(Q44353059)

2 December 2017

Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor (English)

1 reference

2 December 2017

Shozo Furumoto

1

1 reference

2 December 2017

Kyoka Takashima

2

1 reference

2 December 2017

Kazuo Kubota

3

1 reference

2 December 2017

Tatsuo Ido

4

1 reference

2 December 2017

Ren Iwata

5

1 reference

2 December 2017

Hiroshi Fukuda

6

1 reference

2 December 2017

1 February 2003

1 reference

Nuclear Medicine and Biology

2 December 2017

1 reference

2 December 2017

30

1 reference

2 December 2017

2

1 reference

2 December 2017

119-125

1 reference

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

In vivo molecular target assessment of matrix metalloproteinase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Metalloproteinase inhibitors and the prevention of connective tissue breakdown

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Importance of metabolism in pharmacological studies: possible in vitro predictability

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Metastatic potential correlates with enzymatic degradation of basement membrane collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

Design and therapeutic application of matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0969-8051%2802%2900393-1

7 January 2021

10.1016/S0969-8051(02)00393-1

Identifiers

DOI

1 reference

2 December 2017

1 reference